A Multicenter, Open-Label, Single-Arm Trial of the Efficacy and Safety of Empagliflozin Treatment for Refractory Diabetes Mellitus with Insulin Resistance (EMPIRE-01)
ConclusionOur results demonstrate that empagliflozin shows a certain level of efficacy and safety for treatment of insulin resistance syndrome and lipoatrophic diabetes.Trial RegistrationjRCTs2051190029 and NCT04018365.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
More News: Academia | Diabetes | Diabetes Mellitus | Empagliflozin | Endocrinology | Insulin | Japan Health | Jardiance | SGLT2 Inhibitors | Sodium | Study